jurgenfr Shares of Coherus Biosciences ( NASDAQ: CHRS ) rallied 19% Thursday, the day after the company reported higher-than-expected Q3 revenue and disclosed it had restarted production of its biosimilar therapy Udenyca. Coherus reported Q3 net revenue of $70.8M, which included $66.
1M in net sales from Udenyca. Analysts, on.
